Navigation Links
DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting
Date:3/5/2010

WILMINGTON, Mass., March 5 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.

Maintaining efficacy and improving ease of use among providers were paramount to the inception of the enhancements to the BLU-U, which include:

  • Height adjustment using a new rotary design that allows for easier operation  
  • Larger casters and a post handle for easier mobility
  • A pivoting post for compact, small footprint storage and easy movement within the treatment facility

"The mechanical improvements to the BLU-U were specifically designed with practitioners in mind, while still providing them with a highly uniform, efficient, and economic blue light source to treat patients," stated BLU-U co-inventor, Scott Lundahl, DUSA's Vice-President, Regulatory Affairs and Intellectual Property.

The patented BLU-U design utilizes microprocessor feedback control to automatically deliver a consistent, uniform blue light dose to a large treatment area such as the entire face or scalp. In combination with Levulan Kerastick, it is indicated for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face or scalp.  Alone, the BLU-U is specifically cleared for the treatment of moderate inflammatory acne.

About Levulan® PDT and the BLU-U®

Levulan® Kerastick® for Topical Solution plus blue light illumination using the BLU-U blue light photodynamic therapy illuminator is indicated for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face or scalp. AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5M treatment visits per year. DUSA is also in clinical development of its Levulan PDT technology platform for the broad-area treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.

DUSA's patented BLU-U® Blue Light Photodynamic Therapy Illuminator offers effective, non-invasive and pain-free light treatment for moderate inflammatory acne.  Narrow band blue light causes a photodynamic effect within the pilosebaceous gland that kills P. acnes, the bacteria primarily responsible for acne.  BLU-U treatments can be a primary treatment, an alternative to pharmaceuticals and topicals, or an addition to skin care programs.  In September 2003, DUSA received clearance from the U.S. Food and Drug Administration (FDA) to market the BLU-U without Levulan® PDT for the treatment of moderate inflammatory acne vulgaris and general dermatologic conditions.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight. They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms. They form on the outermost layer of skin and they can range in color from skin toned to reddish brown. They can also range in size from as small as a pinhead to larger than a quarter.

About Acne

According to the American Academy of Dermatology, acne is the most common skin disorder in the U.S., affecting 40 to 50 million Americans. There are many types of acne, the most common of which is called acne vulgaris. Just beneath the surface of the skin lie hundreds of tiny glands called sebaceous glands. Their function is to collect and excrete the oily substance called sebum, to keep the skin healthy. However, the tiny pathway for the sebum to escape often becomes clogged and a bacterium called P. acnes grows inside. In a short time, the area swells up and forms a lesion on the skin. At certain times of life, this process becomes very active, troublesome and hard to control.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and other dermatology products. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face or scalp. DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass.  Please visit our website at www.dusapharma.com.

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties.  These forward-looking statements relate to the introduction an enhanced BLU-U Blue Light Photodynamic Therapy Illuminator.  These statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release.  These factors include, without limitation, actions by health regulatory authorities, changing market and regulatory conditions, the maintenance of our patent portfolio, dependence on third-party vendors and manufacturers, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2009.

SOURCE DUSA Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.dusapharma.com

'/>"/>

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FamilyCord Unveils Safer and More Effective Cord Blood Collection Kit
2. Quest Diagnostics Unveils Care360(TM) EHR
3. FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging
4. Slovenias Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB
5. Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use
6. National Expressions of Courage Art Contest Unveils Stories of Inspiration
7. Aflex Unveils Revolutionary New Hose Design for the Chemical and Process Industry
8. Siemens Unveils New Hearing Loss Options at SPLASH: ADAs 2009 Convention
9. Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress
10. Eurotech Unveils New Diabetes Care Management Solution
11. Cleveland Clinic Unveils Top 10 Medical Innovations for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 The global  pacemaker market  is expected ... Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled with the ... Pacemaker globally. In addition, technological enhancements in these devices are supporting the expansion ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
(Date:1/18/2017)... -- Aprima Medical Software, a leading provider of innovative ... revenue cycle management (RCM) solutions for medical practices, ... Healthcare Data Solutions (HDS) of Coral Cables, FL. ... full support for HDS,s customers, which include approximately ... states. Financial terms were not disclosed. ...
Breaking Medicine Technology:
(Date:1/19/2017)... IL (PRWEB) , ... January 19, 2017 , ... ... N.A., announced it recently provided a new $11,250,000 senior credit facility to Sunrise, ... new MB credit facility were used to facilitate a recapitalization of MedPro led ...
(Date:1/19/2017)... Huntington Beach, CA (PRWEB) , ... January 19, ... ... for Oral Health, is now offering treatments for patients with sleep apnea and ... far-reaching consequences for dental and physical health. Dr. Rassouli provides personalized care to ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
(Date:1/19/2017)... ... ... St. Catherine’s Village announced that a limited number of rooms have become available ... grounds of the St. Catherine’s Village campus in Madison, Mississippi that accommodates 120 residents ... Mississippi for the second year in a row by readers of the Clarion-Ledger. , ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California ... rain storm by slowing down and increasing the space between themselves and other vehicles, ... based car accident attorney Raymond R. Hassanlou notes that, rain or shine, drivers should ...
Breaking Medicine News(10 mins):